-
Je něco špatně v tomto záznamu ?
Development of Small-Molecule Antivirals for Ebola
Z. Janeba,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
26172225
DOI
10.1002/med.21355
Knihovny.cz E-zdroje
- MeSH
- antivirové látky chemická syntéza terapeutické užití MeSH
- epidemický výskyt choroby MeSH
- hemoragická horečka Ebola farmakoterapie epidemiologie MeSH
- lidé MeSH
- rychlé screeningové testy MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Geografické názvy
- západní Afrika MeSH
Ebola hemorrhagic fever is a deadly disease caused by infection with one of the Ebola virus species. Although a significant progress has recently been made in understanding of Ebola virus biology and pathogenesis, development of effective anti-Ebola treatments has not been very productive, compared to other areas of antiviral research (e.g., HIV and HCV infections). No approved vaccine or medicine is available for Ebola but several are currently under development. This review summarises attempts in identification, evaluation, and development of small-molecule candidates for treatment of Ebola viral disease, including the most promising experimental drugs brincidofovir (CMX001), BCX4430, and favipiravir (T-705).
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16028370
- 003
- CZ-PrNML
- 005
- 20161025121608.0
- 007
- ta
- 008
- 161005s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/med.21355 $2 doi
- 024 7_
- $a 10.1002/med.21355 $2 doi
- 035 __
- $a (PubMed)26172225
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Janeba, Zlatko $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i. Flemingovo nám. 2, CZ-16610 Prague 6, Czech Republic.
- 245 10
- $a Development of Small-Molecule Antivirals for Ebola / $c Z. Janeba,
- 520 9_
- $a Ebola hemorrhagic fever is a deadly disease caused by infection with one of the Ebola virus species. Although a significant progress has recently been made in understanding of Ebola virus biology and pathogenesis, development of effective anti-Ebola treatments has not been very productive, compared to other areas of antiviral research (e.g., HIV and HCV infections). No approved vaccine or medicine is available for Ebola but several are currently under development. This review summarises attempts in identification, evaluation, and development of small-molecule candidates for treatment of Ebola viral disease, including the most promising experimental drugs brincidofovir (CMX001), BCX4430, and favipiravir (T-705).
- 650 _2
- $a antivirové látky $x chemická syntéza $x terapeutické užití $7 D000998
- 650 _2
- $a epidemický výskyt choroby $7 D004196
- 650 _2
- $a hemoragická horečka Ebola $x farmakoterapie $x epidemiologie $7 D019142
- 650 _2
- $a rychlé screeningové testy $7 D057166
- 650 _2
- $a lidé $7 D006801
- 651 _2
- $a západní Afrika $x epidemiologie $7 D000354
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 773 0_
- $w MED00003265 $t Medicinal research reviews $x 1098-1128 $g Roč. 35, č. 6 (2015), s. 1175-94
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26172225 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20161005 $b ABA008
- 991 __
- $a 20161025122022 $b ABA008
- 999 __
- $a ok $b bmc $g 1166684 $s 953000
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 35 $c 6 $d 1175-94 $e 20150714 $i 1098-1128 $m Medicinal research reviews $n Med Res Rev $x MED00003265
- LZP __
- $a Pubmed-20161005
